Kestra Medical Technologies Ltd 2026年季度报告

Table of Contents PART I.FINANCIAL INFORMATION Item 1.Condensed Consolidated Balance SheetsCondensed Consolidated Statements of Operations and Comprehensive LossCondensed Consolidated Statements of Changes in Redeemable Preferred Stock and Shareholders’ Equity (Deficit) Condensed Consolidated Statements of Cash FlowsNotes to Condensed Consolidated Financial StatementsItem 2.Management’s Discussion and Analysis of Financial Condition and Results of OperationsItem 3.Quantitative and Qualitative Disclosures About Market RiskItem 4.Controls and Procedures PART II.OTHER INFORMATION Item 1.Legal ProceedingsItem 1A.Risk FactorsItem 2.Unregistered Sales of Equity Securities and Use of ProceedsItem 3.Defaults Upon Senior SecuritiesItem 4.Mine Safety DisclosuresItem 5.Other InformationItem 6.ExhibitsSignatures SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q (the “Quarterly Report”) contains “forward-looking” statements within the meaningof the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are basedon our management’s beliefs and assumptions and on information currently available to our management. The forward-looking Forward-looking statements include information concerning our possible or assumed future results of operations, businessstrategies, technology developments, financing and investment plans, dividend policy, competitive position, industry and regulatoryenvironment, potential growth opportunities and the effects of competition. Forward looking statements include statements that arenot historical facts and can be identified by terms such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,”“intend,” “may,” “might,” “objective,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” “will” and “would,” or the Important factors that could cause actual results, performance or achievements to differ materially from our expectationsare described in Part II, Item 1A, “Risk Factors” and elsewhere in this Quarterly Report, and include, but are not limited to, the •our ability to continue to expand the commercialization of our ASSURE WCD, including associated products andservices as part of our Cardiac Recovery System platform, or to commercialize any future product candidates andbegin generating revenue;•our ability to maintain regulatory approvals for our ASSURE WCD and to obtain new regulatory approvals necessaryto distribute our ASSURE WCD in new markets or to distribute additional products we develop in the future;•the rate and degree of market acceptance of our ASSURE WCD or any future product candidates that receive thenecessary marketing and other regulatory approvals;•the availability of reimbursement for our products;•our ability to scale the manufacturing of our ASSURE WCD, obtain sufficient and timely supplies of componentsnecessary to manufacture our ASSURE WCD and effectively manage inventory and distribution;•our ability to hire and retain qualified personnel, including senior management and sales professionals; We caution you that the foregoing list does not contain all of the forward-looking statements made in this QuarterlyReport. More information on factors that could cause our actual results to differ from those expressed in forward-lookingstatements is included from time to time in our reports filed with the Securities and Exchange Commission, (the “SEC”) including Given these uncertainties, we cannot assure you that the forward-looking statements in this Quarterly Report will prove tobe accurate. Also, forward-looking statements represent our management’s beliefs and assumptions only as of the date of thisQuarterly Report and should not be relied upon as representing our expectations or beliefs as of any date subsequent to the time KESTRA MEDICAL TECHNOLOGIES, LTD. AND SUBSIDIARIESCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS(in thousands)(unaudited) KESTRA MEDICAL TECHNOLOGIES, LTD. AND SUBSIDIARIESNOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (in thousands, except share, per share data and percentages) 1. The Company Kestra Medical Technologies, Ltd. is a commercial stage medical device company, which principally generates revenue throughleasing the ASSURE© System, which consists of a Wearable Cardioverter Defibrillator (“WCD”), to patients. Kestra Medical Technologies, Ltd. was formed as a limited company in Bermuda on May 20, 2021 as a wholly owned subsidiary ofWest Affum Holdings, L.P. (“West Affum LP”), a company in the Cayman Islands. Kestra Medical Technologies, Ltd. was formedfor the purpose of completing a public offering and related transactions to carry on the business of West Affum Intermediate West Affum Intermediate Holdings Corp., a Cayman Islands exempted company (“Intermediate Holdings”), was incorporated onAugust 6, 2020, in order to carry on the business of West Affum Holdings Corp. (“WAH Corp.”) and its consolidated su